With such large, apparent Institutional ownership, we would never know when and it they might revolt and seek a takeover, after the beating this Sector and their tech and biotech portfolios just experienced.
Be careful what you wish for! I, for one, would hate to see this happen with so much in our own
pipeline, for I fear a takeover would price sub-30.
Besides the Celldex drugs mentioned below, Pfizer would get cdx-011, cdx-110, cdx-1135, cdx-1127 and others.
CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma
This study is currently recruiting participants.
Verified May 2014 by National Cancer Institute (NCI)
National Cancer Institute (NCI)
Information provided by (Responsible Party):
National Cancer Institute (NCI)ClinicalTrials.gov Identifier:
First received: April 30, 2014
Last updated: May 7, 2014
Last verified: May 2014